Secondary Prevention and RehabilitationCost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels☆,☆☆
Section snippets
Patient characteristics
The cost-effectiveness analysis pertains to survivors of myocardial infarction similar to those enrolled in the CARE trial. In CARE, the mean (SD) age was 59 (9) years. Eighty-six percent of patients were men; among patients assigned to the pravastatin arm, 93% were white, whereas among patients assigned to placebo, 92% were white. The mean cholesterol level at study entry for each group was 209 mg/dL (5.4 mmol/L), with a mean LDL fraction of 139 mg/dL (3.6 mmol/L).3
Effectiveness of therapy
To model the effectiveness
Costs and health-related quality of life
The cost of pravastatin therapy, based on the average dose taken by patients in the active treatment arm in CARE, was $925 per year. The mean cost of other cardiac medications was $1295 per year in the pravastatin group and $1227 per year in the placebo group. The excess medication costs in the pravastatin group were partly offset by savings in hospitalizations (Table I).
Mean health ratings were approximately 1% higher among patients receiving pravastatin: 77.8 versus 77.0 (utility, 0.968 vs
Discussion
Over the last decade, evidence from epidemiologic studies and clinical trials has supported aggressive treatment of hypercholesterolemia and now of average cholesterol levels in patients with CHD.3, 4, 5, 6, 7 Over the same period, statin drugs have surged in popularity because they are effective, well tolerated, and can be taken once or twice a day. Given the expense of statin drugs, however, it has not been clear whether treating patients with CHD who have average cholesterol levels with a
Acknowledgements
We thank Eugene Braunwald, MD, Marc Pfeffer, MD, PhD, and Lemuel Moye, MD, PhD, for helpful input into the analyses; Mae Lipps, RRA, for coding the hospitalization data; Karen Mandell, PharmD, for assigning medication costs; and Loretta Simbartl, MS, for assisting with statistical analyses.
References (34)
- et al.
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease
Am J Cardiol
(1996) Range of serum cholesterol values in the population developing coronary artery disease
Am J Cardiol
(1995)- et al.
Cost-effectiveness of captopril therapy after myocardial infarction
J Am Coll Cardiol
(1995) - et al.
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)
Am J Cardiol
(1993) - et al.
Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome
Control Clin Trials
(1992) NHLBI morbidity and mortality chartbook, 2000
Summary of the second report of the National Cholesterol Education Report (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
JAMA
(1993)- et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
N Engl J Med
(1996) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
N Engl J Med
(1998)Secondary prevention for ischemic heart disease: relative numbers needed to treat with different therapies
Arch Intern Med
(1997)
Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease
Arch Intern Med
Cholesterol reduction: weighing the benefits and risks
Ann Intern Med
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease
JAMA
Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S)
Eur Heart J
Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
N Engl J Med
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population
BMJ
Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study
Circulation
Cited by (82)
The cost-effectiveness of omega-3 polyunsaturated fatty acids – The Australian healthcare perspective
2019, European Journal of Internal MedicineCitation Excerpt :Therefore, our assumption around the duration of treatment effect and time horizon are considered conservative. The majority of studies applied the relative risk reduction/risk difference observed in the trial to represent the treatment effect and only two studies derived the event rate per treatment arm from the trial (based on individual patient level data) [39]. Our study is the first to demonstrate the cost-effectiveness of icosapent ethyl in secondary prevention and a high CVD risk population.
Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population
2016, International Journal of CardiologyEconomic evaluation of lipid-lowering therapy in the secondary prevention setting in the Philippines
2013, Value in Health Regional IssuesCitation Excerpt :However, a cost-utility analysis was performed for the present study. Economic evaluation studies performed in several developed countries using the same secondary prevention setting showed different CERs and ICERs [34–37]. These variations are expected and may be attributed to 1) difference in the identification, measurement, and valuation of costs from country to country and 2) changes in disease prevalence leading to differences in the magnitude of effects of the intervention.
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation
2012, American Journal of CardiologyCost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable
2012, American Journal of CardiologyComparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals
2011, Journal of the American College of CardiologyCitation Excerpt :For both strategies 2 and 3, we accounted for the costs of obtaining the Framingham risk factors by a general practitioner, including laboratory costs. Event-related costs included the costs of hospital stay, diagnostic workup, interventions, and rehabilitation during the first year after an event and were assumed to reflect the average cost after a nonfatal myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention (31,34,45,46). Non-healthcare costs included travel costs and patient time costs.
- ☆
Supported by a grant from Bristol-Myers Squibb. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the manuscript.
- ☆☆
Reprint requests: Joel Tsevat, MD, MPH, Section of Outcomes Research, Division of General Internal Medicine, University of Cincinnati Medical Center, 231 Bethesda Ave, Cincinnati, OH 45267-0535. E-mail: [email protected]